Clonal hematopoiesis of indeterminate potential (CHIP) occurs when blood stem cells acquire mutations enabling their survival and multiplication, often comprising 4%-30% of blood and immune cells.
New research from Stanford Medicine presents a fascinating discovery: a common blood condition known as CHIP may offer a protective effect against Alzheimer’s disease, opening a new frontier in the understanding of neurodegenerative disorders.
Key Points:
- People with CHIP are typically more prone to various diseases including coronary heart disease, chronic liver disease, and blood cancers.
- Recent studies show that individuals with CHIP have a 30%-50% lower risk of developing Alzheimer’s disease compared to those without the CHIP mutation.
Additional Points:
- The level of Alzheimer’s protection in CHIP carriers is comparable to carrying an APOE ε2 allele, a known genetic variant that decreases Alzheimer’s risk.
- In people with CHIP, between 30% and 90% of brain microglia, cells crucial in combating brain inflammation and toxin buildup, harbor CHIP mutations.
- Brain samples of individuals with CHIP showed lower levels of neurofibrillary tangles and amyloid plaques, both associated with Alzheimer’s.
Conclusion:
- Further research is required to understand how mutated microglia might be protecting against Alzheimer’s and the implications for future Alzheimer’s therapeutics.
Hematology Latest Posts
- A Popular Low Calorie Sweetener May Raise the Risk of Blood Clotting
- Abdominal Pain in a Patient with Epistaxis, Telangiectasias, and Arteriovenous Malformations
- Is Luspatercept the New Standard of Care in Transfusion-Dependent Low-Risk Myelodysplastic Syndromes?
- Combination Ponatinib Plus Blinatumomab Shows High Efficacy in Ph-Positive ALL